What is tirzepatide?

GIP and GLP-1 are both incretin hormones — gut hormones released in response to food that signal onward to the pancreas and the brain. Most of the medicines in this space engage the GLP-1 receptor alone. Tirzepatide engages both.

This is why it is inaccurate to describe it as a newer or stronger semaglutide. It is a structurally different peptide with a different receptor profile, developed on a different premise. Comparing the two is a legitimate question; treating one as a version of the other is not.

Like other peptides in the class it is given by subcutaneous injection rather than swallowed, because the digestive tract would break it down.

Tirzepatide is marketed under separate brand names for separate licensed indications — one for type 2 diabetes, one for weight management. Same active ingredient, different licence, different label, and frequently different insurance treatment.

That last point is the practical one. A plan may cover the diabetes brand and exclude the weight-management brand while both contain tirzepatide, because the exclusion is written against the indication rather than the molecule.

The status of compounded GLP-1 preparations is unsettled and we treat it as under review rather than stating it as settled fact. FDA's guidance to compounders sets out an "essentially a copy" test: a compounded product with the same active ingredient as a commercially available drug, in the same or an easily substitutable strength and by the same route, is generally treated as a copy unless a prescriber documents a significant difference for a specific patient. What that means for any particular preparation is a question for the pharmacy and the prescriber, not something a directory can answer for you.

There is no generic tirzepatide in the United States. A compounded preparation is not a generic and has not been through the review an approved product went through.

FDA has documented fraudulent compounded tirzepatide carrying false label information, including at least one adverse event report associated with a product labelled as coming from a pharmacy that did not compound it. If you are supplied a compounded preparation, the name of the pharmacy on the label is a thing worth verifying rather than assuming.

• Is this the FDA-approved product or a compounded preparation, and if compounded, which pharmacy prepares it?
• Which licensed indication is being prescribed against, and does my plan exclude that indication?
• What monitoring is scheduled, and is it included in what I am paying?
• What happens if I have a side effect — who do I reach, and how quickly?
• What is the total monthly cost after any introductory period ends?

Dosing and titration are determined by a licensed provider. We do not publish schedules and you should be wary of anyone who does without knowing your history.

• FDA — FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize — retrieved 2026-08-06
• FDA — FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — retrieved 2026-08-06